--- title: "CX11 | PepTracker Pro" url: https://peptrackerpro.com/peptides/cx11 description: "CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # CX11 Medium Evidence CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results. Aliases CX11 +4 more Evidence Medium Evidence Last Updated 2026-07-15 Reading Time 4 min ## What It Is CX11 is an investigational once-daily oral small-molecule (non-peptide) GLP-1 receptor agonist being developed for obesity, overweight, and type 2 diabetes. It was discovered by Vincentage Pharma Co., Ltd. (China), with global ex-China rights acquired by Corxel Pharmaceuticals in December 2024. Like orforglipron, danuglipron, and aleniglipron, CX11 belongs to the emerging class of small-molecule GLP-1 agonists engineered to reproduce the appetite- and glucose-regulating effects of injectable incretin drugs (semaglutide, tirzepatide) in a scalable, room-temperature-stable pill that avoids cold-chain storage and once-weekly injections. On June 23, 2026, Corxel reported positive top-line results from a U.S. Phase 2 trial (NCT07011797) that enrolled 246 adults with obesity (BMI >= 30) or overweight (BMI 27 to <30 with at least one weight-related comorbidity), randomized 1:1:1:1:1 to CX11 120 mg, 160 mg, 200 mg (slow titration), 200 mg (fast titration), or placebo once daily for 36 weeks. CX11 met its primary endpoints, achieving up to 11.5% weight loss at 36 weeks with weight reduction continuing at a consistent rate and no evidence of a slowing (plateauing) trajectory - a pattern suggesting further loss with longer treatment. The tolerability profile was a headline feature: nausea occurred in 33-34% of participants, vomiting in just 12-16%, diarrhea in 4-12%, and constipation in 2-12%, with no severe GI events and GI adverse events concentrated during dose escalation before subsiding during maintenance. The overall discontinuation rate due to GI adverse events was low at 5.0%. Across more than 1,500 participants studied to date (including the China program), no hepatic safety signal has been identified - an important point given that hepatotoxicity concerns ended Pfizer's first oral GLP-1 candidate lotiglipron and complicated twice-daily danuglipron. The U.S. Phase 2 data were described as consistent with the competitive profile established in Vincentage's positive China Phase 3 obesity program. Corxel plans to advance CX11 into pivotal global Phase 3 studies in weight management, and is also developing CX12, an internally discovered oral small-molecule amylin receptor agonist, plus JX10, a thrombolytic for acute ischemic stroke. Also known as: CX11, CX-11, Corxel oral GLP-1, Vincentage oral GLP-1 receptor agonist, oral small-molecule GLP-1 RA (Corxel/Vincentage) ## Regulatory Status Investigational - not approved U.S. Phase 2 trial (NCT07011797) met its primary endpoints in June 2026 with up to 11.5% weight loss at 36 weeks. Partner Vincentage previously reported positive China obesity Phase 3 results. Corxel plans to initiate pivotal global Phase 3 studies in weight management. Not approved for any indication. Effective: June 2026 View FDA Source (https://www.biospace.com/press-releases/corxel-pharmaceuticals-reports-positive-top-line-results-from-phase-2-trial-of-cx11-in-obese-and-overweight-u-s-adults) ## Why Researchers Study It CX11 is part of the wave of oral non-peptide GLP-1 agonists that could dramatically widen access to incretin-based obesity therapy by removing the injection, cold-chain, and manufacturing-scale barriers of peptide drugs. Its Phase 2 profile is of particular interest because it pairs double-digit weight loss with a markedly low vomiting rate and a clean hepatic safety record across >1,500 participants - the two attributes (tolerability and liver safety) that have most often tripped up earlier oral GLP-1 candidates. ## Proposed Mechanisms - Small-molecule agonism of the GLP-1 receptor, reducing appetite and caloric intake - Delays gastric emptying to promote satiety and reduce food intake - Enhances glucose-dependent insulin secretion, supporting glycemic control - Non-peptide structure allows once-daily oral dosing without the absorption enhancers or strict fasting requirements of peptide-based oral GLP-1s ## Evidence Snapshot Medium Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Phase 2 (U.S., NCT07011797) - randomized, double-blind, placebo-controlled | 246 adults with obesity (BMI >= 30) or overweight (BMI 27 to <30 + comorbidity) - 36 weeks, once-daily oral | Met primary endpoints: up to 11.5% weight loss at 36 weeks with no plateau; low GI burden (nausea 33-34%, vomiting 12-16%, diarrhea 4-12%, constipation 2-12%); 5.0% discontinuation due to GI AEs; no hepatic safety signal | Source: https://www.biospace.com/press-releases/corxel-pharmaceuticals-reports-positive-top-line-results-from-phase-2-trial-of-cx11-in-obese-and-overweight-u-s-adults | | Phase 3 (China, Vincentage Pharma) | Adults with obesity/overweight - oral CX11 | Positive obesity Phase 3 results reported by partner Vincentage; described as establishing the competitive profile confirmed in the U.S. Phase 2 trial | Source: https://www.biospace.com/press-releases/corxel-pharmaceuticals-reports-positive-top-line-results-from-phase-2-trial-of-cx11-in-obese-and-overweight-u-s-adults | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Researching CX11? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=cx11) ## Safety & Cautions - Investigational - not approved for any indication; Phase 2 (U.S.) and Phase 3 (China) completed, global Phase 3 not yet started - Top-line results only; full peer-reviewed data and detailed dose-response not yet published - GI adverse events (nausea, vomiting, diarrhea, constipation) common, mainly during dose escalation - China Phase 3 results reported by the partner rather than in a peer-reviewed journal at time of writing; cross-trial comparisons with orforglipron, aleniglipron, and oral semaglutide have significant limitations - Long-term safety, durability of weight loss, and cardiovascular outcomes not yet established ## Comparisons See how CX11 compares to related peptides: CX11 vs Aleniglipron: https://peptrackerpro.com/compare/cx11-vs-aleniglipron CX11 vs Conveglipron: https://peptrackerpro.com/compare/cx11-vs-conveglipron CX11 vs Danuglipron: https://peptrackerpro.com/compare/cx11-vs-danuglipron CX11 vs Ecnoglutide: https://peptrackerpro.com/compare/cx11-vs-ecnoglutide CX11 vs Orforglipron: https://peptrackerpro.com/compare/cx11-vs-orforglipron CX11 vs Semaglutide: https://peptrackerpro.com/compare/cx11-vs-semaglutide ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults - BioSpace (June 23, 2026) PubMed (https://www.biospace.com/press-releases/corxel-pharmaceuticals-reports-positive-top-line-results-from-phase-2-trial-of-cx11-in-obese-and-overweight-u-s-adults) 2. [2] Corxel to advance oral obesity drug to Phase III trials - Clinical Trials Arena (2026) PubMed (https://www.clinicaltrialsarena.com/news/corxel-to-advance-oral-obesity-drug-to-phase-iii-trials/) 3. [3] CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports - HCPLive (2026) PubMed (https://www.hcplive.com/view/cx11-shows-weight-loss-in-phase-2-obesity-trial-corxel-reports) 4. [4] Corxel gears up for global pivotal push after oral GLP-1 posts 'competitive' phase 2 results - Fierce Biotech (2026) PubMed (https://www.fiercebiotech.com/biotech/corxel-gears-global-pivotal-push-after-oral-glp-1-posts-competitive-ph-2-results) ### Keep researching in the app - Log CX11 to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=cx11 Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Aleniglipron Medium Evidence An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/aleniglipron \+ Compare: https://peptrackerpro.com/compare?select=aleniglipron Track in App: https://app.peptrackerpro.com/?add=aleniglipron ### Conveglipron Low Evidence An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/conveglipron \+ Compare: https://peptrackerpro.com/compare?select=conveglipron Track in App: https://app.peptrackerpro.com/?add=conveglipron ### Danuglipron Medium Evidence An oral small-molecule GLP-1 receptor agonist discontinued by Pfizer in 2026 after a potential drug-induced liver injury signal, despite showing meaningful weight loss in Phase 2b. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/danuglipron \+ Compare: https://peptrackerpro.com/compare?select=danuglipron Track in App: https://app.peptrackerpro.com/?add=danuglipron ### Ecnoglutide High Evidence A cAMP signaling-biased GLP-1 receptor agonist approved in China for chronic weight management, with Phase 3 data showing up to 15.4% weight loss. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/ecnoglutide \+ Compare: https://peptrackerpro.com/compare?select=ecnoglutide Track in App: https://app.peptrackerpro.com/?add=ecnoglutide ### Orforglipron High Evidence The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/orforglipron \+ Compare: https://peptrackerpro.com/compare?select=orforglipron Track in App: https://app.peptrackerpro.com/?add=orforglipron ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "CX11", "description": "CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results.", "url": "https://peptrackerpro.com/peptides/cx11", "lastReviewed": "2026-07-15", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "CX11", "item": "https://peptrackerpro.com/peptides/cx11" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People interested in oral weight-loss medications that avoid injections?", "acceptedAnswer": { "@type": "Answer", "text": "CX11 is a research peptide studied in preclinical models. CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results." } }, { "@type": "Question", "name": "Those following the emerging oral small-molecule GLP-1 competitive landscape?", "acceptedAnswer": { "@type": "Answer", "text": "CX11 is a research peptide studied in preclinical models. CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results." } }, { "@type": "Question", "name": "Individuals comparing tolerability and liver-safety profiles across oral GLP-1 candidates?", "acceptedAnswer": { "@type": "Answer", "text": "CX11 is a research peptide studied in preclinical models. CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results." } } ] } ] ```